Key Highlights
- Third-quarter net Revenue rose 4.1% to USD 1.49 billion from USD 1.44 billion, led by high single-digit growth in the acute therapy portfolio.
- Net income increased 10.8% to USD 57.4 million, or USD 0.38 per diluted share, compared with USD 51.8 million, or USD 0.32 per share, a year earlier.
- Operating income rose to USD 89.2 million from USD 84.5 million, even though selling, general and administrative costs included Transaction Costs for the pending merger.
- A Merger agreement dated October 5, 2026 would pay USD 32.05 in cash per share, with closing expected in the first half of calendar 2027.
Acute Therapies Drive a 4.1% Revenue Gain at Option Care Health (NASDAQ:OPCH)
Option Care Health (NASDAQ:OPCH) filed its Quarterly Report on November 4, 2026 for the period ended September 30. The company provides home and alternate site infusion services. Net revenue was USD 1,493.5 million against USD 1,435.0 million, while Gross Profit rose 4.4% to USD 285.0 million, a Margin of 19.1% versus 19.0%. Management credited growth in higher-margin therapies and ongoing operating efficiencies. Nine-month revenue was USD 4.29 billion, up 2.5%, with nine-month Net Income of USD 156.7 million, or USD 1.02 per diluted share, versus USD 149.1 million, or USD 0.91.
Merger Costs, Debt Refinancing and Tax Shape the Profit Line
Selling, general and administrative expenses rose 3.2% to USD 177.6 million, which the company attributed mainly to merger transaction costs. Net interest expense fell to USD 12.9 million from USD 14.1 million. The Other, net line swung to a USD 1.0 million gain from a USD 3.6 million loss, a change the filing mainly attributes to a USD 4.7 million loss on debt extinguishment from a refinancing in the third quarter of 2025, with no comparable item this year. Income tax expense rose 25.2% to USD 21.5 million. Cash and cash equivalents were USD 299.1 million, compared with USD 232.6 million at December 31, 2025, even after USD 167.5 million of share repurchases during the first nine months.
The USD 32.05 Cash Deal: Conditions, Fees and Buyback Freeze
Under the agreement, an investor group of affiliates of Clayton, Dubilier & Rice and McKesson would acquire the company, and its shares would cease to be publicly listed. Closing requires a majority stockholder vote, expiry of the Hart-Scott-Rodino Waiting Period and healthcare regulatory approvals, and either side can terminate if closing has not occurred by October 5, 2027. A termination fee of about USD 145.96 million is payable by the company in certain cases. The deal limits dividends and repurchases without the buyer's consent. The company bought back 7.9 million shares for USD 167.5 million this year, with none in the third quarter. The average price paid was USD 21.26 a share, so the USD 32.05 offer is about 51% above that average (calculated).
Where Things Stand
The results are steady rather than transformative, and the deal now frames them. Option Care Health (NASDAQ:OPCH) grew revenue 4.1%, net income 10.8% and diluted EPS to USD 0.38 while carrying merger costs. The USD 32.05 cash price is fixed regardless of Business performance, so future growth would not accrue to holders. The filing lists risks including regulatory approvals, a stockholder vote, litigation challenging the transaction, and operating disruption. Next markers are the stockholder meeting, regulatory clearances and the first-half 2027 closing target.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...